AHB (IFC-49198)

Countries
  • China
Geographic location where the impacts of the investment may be experienced.
Financial Institutions
  • International Finance Corporation (IFC)
International, regional and national development finance institutions. Many of these banks have a public interest mission, such as poverty reduction.
Project Status
Proposed
Stage of the project cycle. Stages vary by development bank and can include: pending, approval, implementation, and closed or completed.
Bank Risk Rating
B
Environmental and social categorization assessed by the development bank as a measure of the planned project’s environmental and social impacts. A higher risk rating may require more due diligence to limit or avoid harm to people and the environment. For example, "A" or "B" are risk categories where "A" represents the highest amount of risk. Results will include projects that specifically recorded a rating, all other projects are marked ‘U’ for "Undisclosed."
Borrower
Anhui Huaheng Biotechnology Co.,Ltd
A public entity (government or state-owned) provided with funds or financial support to manage and/or implement a project.
Sectors
  • Industry and Trade
The service or industry focus of the investment. A project can have several sectors.
Investment Type(s)
Loan
The categories of the bank investment: loan, grant, guarantee, technical assistance, advisory services, equity and fund.
Investment Amount (USD)
$ 70.50 million
Value listed on project documents at time of disclosure. If necessary, this amount is converted to USD ($) on the date of disclosure. Please review updated project documents for more information.
Project Cost (USD)
$ 105.00 million
Value listed on project documents at time of disclosure. If necessary, this amount is converted to USD ($) on the date of disclosure. Please review updated project documents for more information.
Bank Documents
Primary Source

Original disclosure @ IFC website

Updated in EWS Mar 17, 2025

Disclosed by Bank Nov 20, 2024

Contribute Information
Can you contribute information about this project?
Contact the EWS Team

Project Description
If provided by the financial institution, the Early Warning System Team writes a short summary describing the purported development objective of the project and project components. Review the complete project documentation for a detailed description.

According to the Bank’s website, IFC is proposing to provide up to RMB 500 million (equivalent to US$70.5 million) in the form of a Green Loan (the Loan) to Qinhuangdao Huaheng Bioengineering Co., Ltd. (QHB), a wholly-owned subsidiary of Anhui Huaheng Biotechnology Co., Ltd. (AHB). The IFC proceeds will be used to fund the capex and working capital needs of malic acid and L-Tryptophan production (the Project).                                      

Early Warning System Project Analysis
For a project with severe or irreversible impacts to local community and natural resources, the Early Warning System Team may conduct a thorough analysis regarding its potential impacts to human and environmental rights.

This is a Category B project according to IFC’s Policy on Environmental and Social Sustainability (2012). Key E&S issues associated with this Project include: 1) AHB’s management and monitoring systems to assess and manage E&S risks and impacts from its operations, as well as those related to the supply chains for the facilities covered under the project; 2) management and monitoring of air emissions, wastewater, and hazardous wastes and materials; 3) consistent management of labor and working conditions including occupational health and safety; 4) energy and resource efficiency measures; 5) life and fire safety (LFS) and emergency preparedness and response (EPR) management; 6) AHB’s stakeholder engagement activities related to E&S aspects.

Investment Description
Here you can find a list of individual development financial institutions that finance the project.

The total Project is estimated to cost approximately US$105 million, among which IFC will finance up to RMB 500 million (equivalent to US$70.5 million) in the form of a Green Loan, and the remaining will be covered by the Company’s internal cash.

Private Actors Description
A Private Actor is a non-governmental body or entity that is the borrower or client of a development project, which can include corporations, private equity and banks. This describes the private actors and their roles in relation to the project, when private actor information is disclosed or has been further researched.

Anhui Huaheng Biotechnology Co., Ltd. (AHB) is a leading manufacturer of amino acids and other bio-based products in the People’s Republic of China (PRC).

Qinhuangdao Huaheng Bioengineering Co., Ltd. is a wholly-owned subsidiary of AHB.

Ms. GUO Henghua is the Founder and Chairwoman of AHB, holding a stake of 27.15%. The remaining shares are held by individuals, institutional investors and other investors from public market, with each representing less than 5% of the shareholding of AHB.

Private Actor 1 Private Actor 1 Role Private Actor 1 Sector Relation Private Actor 2 Private Actor 2 Role Private Actor 2 Sector
- - - - Anhui Huaheng Biotechnology Co., Ltd. Client -
- - - - Qinhuangdao Huaheng Bioengineering Co., Ltd. Subsidiary -

Contact Information
This section aims to support the local communities and local CSO to get to know which stakeholders are involved in a project with their roles and responsibilities. If available, there may be a complaint office for the respective bank which operates independently to receive and determine violations in policy and practice. Independent Accountability Mechanisms receive and respond to complaints. Most Independent Accountability Mechanisms offer two functions for addressing complaints: dispute resolution and compliance review.

Qinhuangdao Huaheng Bioengineering Co., Ltd.
Mr. Wu Xu
General Manager
+86-152-554-73767
xw@ehuaheng.com
18 Shenshan Road, Shan Haiguan District, Qinhuangdao, Hebei Province, PRC
Websitewww.huahengbio.com

ACCESS TO INFORMATION

You can submit a request for information disclosure at: https://disclosures.ifc.org/#/inquiries

If you believe that your request for information from IFC has been unreasonably denied, or that this Policy has been interpreted incorrectly, you can submit a complaint at the link above to IFC's Access to Information Policy Advisor, who reports directly to IFC's Executive Vice President.

ACCOUNTABILITY MECHANISM OF IFC/MIGA

The Compliance Advisor Ombudsman (CAO) is the independent complaint mechanism and fact-finding body for people who believe they are likely to be, or have been, adversely affected by an IFC or MIGA- financed project. If you submit a complaint to the CAO, they may assist you in resolving a dispute with the company and/or investigate to assess whether the IFC is following its own policies and procedures for preventing harm to people or the environment. If you want to submit a complaint electronically, you can email the CAO at CAO@worldbankgroup.org You can learn more about the CAO and how to file a complaint at http://www.cao-ombudsman.org

How it works

How it works